OBI-992

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameOBI-992
Drug Alias NameOBI-992BSI-992BSI992R-992BSI-04702
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionAnti-Trop-2DNA topoisomerase I inhibitors
TargetsTumor-associated calcium signal transducer 2DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiosion Inc
China Registration ClassN/A

Develop Information

Active CompaniesObi Pharma Usa IncObi Pharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A